MIRUM PHARMA CEO SAYS ADDITION OF BRELOVITUG TO PIPELINE WILL BRING REVENUE POTENTIAL OF RARE DISEASE PORTFOLIO TO OVER $4 BLN - CONF CALL

Reuters · 1d ago

Please log in to view news